Award
NIH Reporter #1R01CA302934-01A1
Defining biomarkers and overcoming resistance to DLL3-targeting immune therapies in lung cancer
Recipient
Not Specified
Award Amount
$671,740.00
Ceiling
$671,740.00
Awarded
July 23, 2026
Identifier
1R01CA302934-01A1
Award for research on biomarkers and resistance mechanisms to DLL3-targeting immune therapies in lung cancer, funded by NIH/NCI with $671,740.
Description
This project aims to identify biomarkers and develop strategies to overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. It involves multidisciplinary research including preclinical models, biomarker analysis, and clinical trials. The award is funded by the NIH/NCI with a total budget of $671,740 for fiscal year 2026.